MEI Pharma
MEI Pharma focuses on developing novel cancer therapies, particularly for hematologic malignancies and solid tumors, with key programs including Voruciclib and ME-344.
Company Overview of MEI Pharma
MEI Pharma is focused on developing cancer therapies that are best-in-class and aim to address known drug resistance mechanisms. The company is located at 11455 El Camino Real, Suite 250, San Diego, CA 92130. MEI Pharma concentrates on both hematologic malignancies and solid tumors, with a goal to provide benefits to patients through data-driven decisions.
MEI Pharma Services for Patients and Caregivers
MEI Pharma offers dedicated information and resources for patients and caregivers. This includes providing access to clinical trials that are part of their development pipeline. By engaging with patients and caregivers, the company ensures that its therapies are developed with a clear focus on patient needs and outcomes.
MEI Pharma Oncology Pipeline
MEI Pharma's oncology pipeline includes significant programs such as Voruciclib and ME-344. These investigational therapies target various forms of cancer, including relapsed metastatic colorectal cancer. Notably, the company has reported initial data from clinical studies evaluating ME-344 in combination with Bevacizumab (Avastin®).
Research and Development at MEI Pharma
MEI Pharma is committed to leveraging collaborations to enhance its research and development efforts. The company uses data-driven decisions to advance its strategy, particularly focusing on its key programs, Voruciclib and ME-344, in treating hematologic malignancies and solid tumors. MEI Pharma continuously works to develop novel and differentiated cancer therapies.
MEI Pharma Financial Reporting
MEI Pharma publishes annual reports and quarterly financial results to maintain transparency and keep stakeholders informed about its progress. These reports reflect the company's commitment to financial accountability and the advancement of its oncology-focused programs.